4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone modulation of cytokine release in U937 human macrophages.

Abstract

The nicotine-derived N-nitrosamine, 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK), is one of the most abundant and potent carcinogens found in tobacco smoke. NNK induces lung tumors in rodents and is most likely involved in lung carcinogenesis in humans. Studies on the metabolism and carcinogenicity of NNK have been extensive. However, its effects on the immune system have not been investigated thoroughly. Considering that tobacco smoking partially suppresses the immune response in humans, and that immune surveillance plays a critical role in cancer development, we examined the effects of NNK on the production of selected cytokines. In a previous study, we observed an inhibition of NK cell activity and IgM secretory cell number in NNK-treated A/J mice [Rioux and Castonguay (1997) J Natl Cancer Inst 89: 874]. In this study, we demonstrate that U937 human macrophages activate NNK to alkylating intermediates by alpha-carbon hydroxylation and detoxify NNK by N-oxidation. We observed that NNK, following activation, induces the release of soluble tumor necrosis factor (TNF), but inhibits interleukin(IL)-10 synthesis. We also report that 4-(acetoxymethylnitrosamino)-1-(3-pyridyl)- -butanone, and nitroso(acetoxymethyl)methylamine, which generate the same alkylating intermediates as NNK, have similar effects on TNF and IL-10. This suggests that pyridyloxobutylating and methylating intermediates generated from NNK are potent modulators of the immune response. The levels of IL-6, granulocyte/macrophage-colony-stimulating factor and macrophage chemotactic protein 1 were also decreased in supernatants of NNK-treated U937 macrophages. In contrast, IL-2 synthesis in Jurkat cells was inhibited by NNK treatment. This is the first study demonstrating that NNK, via its alkylating intermediates, alters the cytokine synthesis profile in human cells. Modulation of cytokine synthesis by NNK might partially explain the immunosuppresion observed in smokers. Inhibition of immune functions, resulting from NNK activation to alkylating agents, may facilitate lung tumor development.

• Authors: N Rioux, A Castonguay
• Journal: Cancer immunology, immunotherapy : CII (Cancer Immunol Immunother) Vol. 49 Issue 12 Pg. 663-70 (Feb 2001) ISSN: 0340-7004 [Print] Germany
• PMID: 11258792 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Carcinogens
• Chemokine CCL2
• Cytokines
• Interleukin-2
• Interleukin-6
• Nitrosamines
• Tumor Necrosis Factor-alpha
• Interleukin-10
• Interleukin-12
• 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone
• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Alkylation
• Carcinogens (pharmacology)
• Chemokine CCL2 (metabolism)
• Cytokines (metabolism)
• Granulocyte-Macrophage Colony-Stimulating Factor (metabolism)
• Humans
• Interleukin-10 (metabolism)
• Interleukin-12 (metabolism)
• Interleukin-2 (metabolism)
• Interleukin-6 (metabolism)
• Lung (drug effects, metabolism)
• Lung Neoplasms (chemically induced)
• Lymphoma (pathology)
• Macrophages (drug effects, metabolism)
• Molecular Structure
• Nitrosamines (pharmacology)
• Tumor Necrosis Factor-alpha (metabolism)
• U937 Cells (drug effects, metabolism)